Negyedszázados tapasztalat a hazai terhességi trofoblasztbetegségek ellátásában

Translated title of the contribution: Gestational trophoblastic neoplasia in Hungary

Iván Szigetvári, János Szepesi, György Végh, József Bátorfi, Zoltán Nagymányoki, Gabriella Arató, István Gáti, V. Fülöp

Research output: Contribution to journalArticle

Abstract

The authors review their clinical experience with the treatment of gestational trophoblastic neoplasia (GTN) over the past 25 years at the Hungarian National Trophoblastic Disease Center. Between 1st January, 1977 and 31st December, 2001 the authors treated 355 patients with GTN referred from all parts of Hungary. The patients' age varied between 14-53 years, the average being 28.3 years. The patients were selected for primary chemotherapy based upon the anatomical staging and prognostic score factors of the GTD (gestational trophoblastic disease). Out of 173 patients remission was achieved in 162 (93.2%) as a result of methotrexate therapy. In case of 11 patients (6.8%) they could obtain a complete remission by using a combination chemotherapy, in some cases assisted by operation. 5 of these 11 patients have had high-risk disease. In case of another 68 patients remission could be achieved in 63 (92.6%) as a result of Actinomycin-D therapy, whereas in 5 cases (7.4%) by a secondary combination chemotherapy. Two out of these 5 patients had a high risk disease. Chemotherapy, surgical intervention or other supplementary treatments resulted in a 100% successful therapy in cases of non-metastatic and low-risk metastatic disease in patients with GTD 95.9% curring rate (in 116 of 121 patients) was achieved in group of patients with high risk GTD using combined chemotherapy (MAC, EMA-CO, CEB) as primary treatment 98.6% total remission rate (in 350 of 355 patients) was achieved in patients with GTD at authors' center over the past 25 years. Data support the concept that patient care under the guidance of experienced clinicians serves to optimize the opportunity for cure and minimize morbidity. According to the experiences the middle-dose methotrexate or Actinomycin-D therapy should be selected as primary treatment in patients with non-metastatic or low-risk metastatic GTD. It is of importance to note that in cases of patients with a disease resistant to single agent chemotherapy, complete remission can regularly be achieved by using a combined chemotherapy. Necessary to emphasize that combined chemotherapy must be selected for primary treatment of patients with high risk GTD.

Original languageHungarian
Pages (from-to)543-553
Number of pages11
JournalMagyar Noorvosok Lapja
Volume69
Issue number6
Publication statusPublished - 2006

Fingerprint

Gestational Trophoblastic Disease
Hungary
Drug Therapy
Therapeutics
Dactinomycin
Combination Drug Therapy
Methotrexate

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Szigetvári, I., Szepesi, J., Végh, G., Bátorfi, J., Nagymányoki, Z., Arató, G., ... Fülöp, V. (2006). Negyedszázados tapasztalat a hazai terhességi trofoblasztbetegségek ellátásában. Magyar Noorvosok Lapja, 69(6), 543-553.

Negyedszázados tapasztalat a hazai terhességi trofoblasztbetegségek ellátásában. / Szigetvári, Iván; Szepesi, János; Végh, György; Bátorfi, József; Nagymányoki, Zoltán; Arató, Gabriella; Gáti, István; Fülöp, V.

In: Magyar Noorvosok Lapja, Vol. 69, No. 6, 2006, p. 543-553.

Research output: Contribution to journalArticle

Szigetvári, I, Szepesi, J, Végh, G, Bátorfi, J, Nagymányoki, Z, Arató, G, Gáti, I & Fülöp, V 2006, 'Negyedszázados tapasztalat a hazai terhességi trofoblasztbetegségek ellátásában', Magyar Noorvosok Lapja, vol. 69, no. 6, pp. 543-553.
Szigetvári I, Szepesi J, Végh G, Bátorfi J, Nagymányoki Z, Arató G et al. Negyedszázados tapasztalat a hazai terhességi trofoblasztbetegségek ellátásában. Magyar Noorvosok Lapja. 2006;69(6):543-553.
Szigetvári, Iván ; Szepesi, János ; Végh, György ; Bátorfi, József ; Nagymányoki, Zoltán ; Arató, Gabriella ; Gáti, István ; Fülöp, V. / Negyedszázados tapasztalat a hazai terhességi trofoblasztbetegségek ellátásában. In: Magyar Noorvosok Lapja. 2006 ; Vol. 69, No. 6. pp. 543-553.
@article{7d79edf02f7b482d8c8b67fe59185e9d,
title = "Negyedsz{\'a}zados tapasztalat a hazai terhess{\'e}gi trofoblasztbetegs{\'e}gek ell{\'a}t{\'a}s{\'a}ban",
abstract = "The authors review their clinical experience with the treatment of gestational trophoblastic neoplasia (GTN) over the past 25 years at the Hungarian National Trophoblastic Disease Center. Between 1st January, 1977 and 31st December, 2001 the authors treated 355 patients with GTN referred from all parts of Hungary. The patients' age varied between 14-53 years, the average being 28.3 years. The patients were selected for primary chemotherapy based upon the anatomical staging and prognostic score factors of the GTD (gestational trophoblastic disease). Out of 173 patients remission was achieved in 162 (93.2{\%}) as a result of methotrexate therapy. In case of 11 patients (6.8{\%}) they could obtain a complete remission by using a combination chemotherapy, in some cases assisted by operation. 5 of these 11 patients have had high-risk disease. In case of another 68 patients remission could be achieved in 63 (92.6{\%}) as a result of Actinomycin-D therapy, whereas in 5 cases (7.4{\%}) by a secondary combination chemotherapy. Two out of these 5 patients had a high risk disease. Chemotherapy, surgical intervention or other supplementary treatments resulted in a 100{\%} successful therapy in cases of non-metastatic and low-risk metastatic disease in patients with GTD 95.9{\%} curring rate (in 116 of 121 patients) was achieved in group of patients with high risk GTD using combined chemotherapy (MAC, EMA-CO, CEB) as primary treatment 98.6{\%} total remission rate (in 350 of 355 patients) was achieved in patients with GTD at authors' center over the past 25 years. Data support the concept that patient care under the guidance of experienced clinicians serves to optimize the opportunity for cure and minimize morbidity. According to the experiences the middle-dose methotrexate or Actinomycin-D therapy should be selected as primary treatment in patients with non-metastatic or low-risk metastatic GTD. It is of importance to note that in cases of patients with a disease resistant to single agent chemotherapy, complete remission can regularly be achieved by using a combined chemotherapy. Necessary to emphasize that combined chemotherapy must be selected for primary treatment of patients with high risk GTD.",
keywords = "Anatomical staging, Chemotherapy, Gestational trophoblastic neoplasia, Prognostic score",
author = "Iv{\'a}n Szigetv{\'a}ri and J{\'a}nos Szepesi and Gy{\"o}rgy V{\'e}gh and J{\'o}zsef B{\'a}torfi and Zolt{\'a}n Nagym{\'a}nyoki and Gabriella Arat{\'o} and Istv{\'a}n G{\'a}ti and V. F{\"u}l{\"o}p",
year = "2006",
language = "Hungarian",
volume = "69",
pages = "543--553",
journal = "Magyar Noorvosok Lapja",
issn = "0025-021X",
publisher = "Magyar Noovos Tarsasag",
number = "6",

}

TY - JOUR

T1 - Negyedszázados tapasztalat a hazai terhességi trofoblasztbetegségek ellátásában

AU - Szigetvári, Iván

AU - Szepesi, János

AU - Végh, György

AU - Bátorfi, József

AU - Nagymányoki, Zoltán

AU - Arató, Gabriella

AU - Gáti, István

AU - Fülöp, V.

PY - 2006

Y1 - 2006

N2 - The authors review their clinical experience with the treatment of gestational trophoblastic neoplasia (GTN) over the past 25 years at the Hungarian National Trophoblastic Disease Center. Between 1st January, 1977 and 31st December, 2001 the authors treated 355 patients with GTN referred from all parts of Hungary. The patients' age varied between 14-53 years, the average being 28.3 years. The patients were selected for primary chemotherapy based upon the anatomical staging and prognostic score factors of the GTD (gestational trophoblastic disease). Out of 173 patients remission was achieved in 162 (93.2%) as a result of methotrexate therapy. In case of 11 patients (6.8%) they could obtain a complete remission by using a combination chemotherapy, in some cases assisted by operation. 5 of these 11 patients have had high-risk disease. In case of another 68 patients remission could be achieved in 63 (92.6%) as a result of Actinomycin-D therapy, whereas in 5 cases (7.4%) by a secondary combination chemotherapy. Two out of these 5 patients had a high risk disease. Chemotherapy, surgical intervention or other supplementary treatments resulted in a 100% successful therapy in cases of non-metastatic and low-risk metastatic disease in patients with GTD 95.9% curring rate (in 116 of 121 patients) was achieved in group of patients with high risk GTD using combined chemotherapy (MAC, EMA-CO, CEB) as primary treatment 98.6% total remission rate (in 350 of 355 patients) was achieved in patients with GTD at authors' center over the past 25 years. Data support the concept that patient care under the guidance of experienced clinicians serves to optimize the opportunity for cure and minimize morbidity. According to the experiences the middle-dose methotrexate or Actinomycin-D therapy should be selected as primary treatment in patients with non-metastatic or low-risk metastatic GTD. It is of importance to note that in cases of patients with a disease resistant to single agent chemotherapy, complete remission can regularly be achieved by using a combined chemotherapy. Necessary to emphasize that combined chemotherapy must be selected for primary treatment of patients with high risk GTD.

AB - The authors review their clinical experience with the treatment of gestational trophoblastic neoplasia (GTN) over the past 25 years at the Hungarian National Trophoblastic Disease Center. Between 1st January, 1977 and 31st December, 2001 the authors treated 355 patients with GTN referred from all parts of Hungary. The patients' age varied between 14-53 years, the average being 28.3 years. The patients were selected for primary chemotherapy based upon the anatomical staging and prognostic score factors of the GTD (gestational trophoblastic disease). Out of 173 patients remission was achieved in 162 (93.2%) as a result of methotrexate therapy. In case of 11 patients (6.8%) they could obtain a complete remission by using a combination chemotherapy, in some cases assisted by operation. 5 of these 11 patients have had high-risk disease. In case of another 68 patients remission could be achieved in 63 (92.6%) as a result of Actinomycin-D therapy, whereas in 5 cases (7.4%) by a secondary combination chemotherapy. Two out of these 5 patients had a high risk disease. Chemotherapy, surgical intervention or other supplementary treatments resulted in a 100% successful therapy in cases of non-metastatic and low-risk metastatic disease in patients with GTD 95.9% curring rate (in 116 of 121 patients) was achieved in group of patients with high risk GTD using combined chemotherapy (MAC, EMA-CO, CEB) as primary treatment 98.6% total remission rate (in 350 of 355 patients) was achieved in patients with GTD at authors' center over the past 25 years. Data support the concept that patient care under the guidance of experienced clinicians serves to optimize the opportunity for cure and minimize morbidity. According to the experiences the middle-dose methotrexate or Actinomycin-D therapy should be selected as primary treatment in patients with non-metastatic or low-risk metastatic GTD. It is of importance to note that in cases of patients with a disease resistant to single agent chemotherapy, complete remission can regularly be achieved by using a combined chemotherapy. Necessary to emphasize that combined chemotherapy must be selected for primary treatment of patients with high risk GTD.

KW - Anatomical staging

KW - Chemotherapy

KW - Gestational trophoblastic neoplasia

KW - Prognostic score

UR - http://www.scopus.com/inward/record.url?scp=33846181322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846181322&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33846181322

VL - 69

SP - 543

EP - 553

JO - Magyar Noorvosok Lapja

JF - Magyar Noorvosok Lapja

SN - 0025-021X

IS - 6

ER -